On March 18, 2026, the University of Calgary is set to advance its research into the therapeutic effects of THC capsules. This clinical trial, led by Dr. Leah Mayo, involves 24 healthy adults who are participating in a study aimed at understanding how different doses of THC can impact anxiety and stress levels.

Participants in the trial are taking capsules containing varying amounts of THC: 6, 9, or 15 milligrams, alongside a placebo group. The primary objective of the study is to map the therapeutic window for oral THC, which could potentially lead to new treatments for anxiety disorders.

The trial utilizes a proprietary Self-Emulsifying Drug Delivery System (SEDDs) technology developed by Avicanna Inc, the company supplying the THC capsules. This innovative approach aims to enhance the bioavailability of THC, making it more effective for therapeutic use.

Dr. Leah Mayo has noted, “With some doses, people feel a reduction in their anxiety, but at higher doses, they can feel an increase in anxiety.” This insight underscores the complexity of dosing in cannabinoid therapies and the need for comprehensive research.

Avicanna, which has been deepening its ties with Canadian research institutions, generated approximately C$18.9 million in revenue over the nine months ending September 30, 2025, and has achieved a gross margin of 52 percent. The company has also eliminated its debt and is progressing towards positive adjusted EBITDA.

In addition to this trial, the University of Calgary is actively participating in national teams that study the effects of cannabis on brain health and cardiovascular risks, further solidifying its role in cannabis research.

The findings from this clinical trial could have significant implications for the understanding of THC’s effects on mental health, potentially guiding future therapeutic applications. As the research community continues to explore the benefits of cannabinoids, the outcomes of this study will be closely monitored.

As of now, the trial is ongoing, and the results are anticipated to contribute valuable data to the field of cannabinoid research. The implications of this research extend beyond the participants, potentially impacting treatment options for individuals suffering from anxiety and stress-related disorders.

Сообщение University of Calgary’s Clinical Trial on THC Capsules появились сначала на YourTownNews.